Ezgi Tanriver-Ayder

Ezgi Tanriver-Ayder

Auto-generated profile, based on publicly available information

Ezgi Tanriver-Ayder

Centre for Clinical Brain Sciences, Edinburgh Medical School, The University of Edinburgh, Edinburgh, Scotland, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in BMJ Open Science
Verified
Journal Article
Open access
PDF file
ETEzgi Tanriver-Ayder
Ezgi Tanriver-Ayder
CFChristel Faes
Christel Faes
TCTom van de Casteele
Tom van de Casteele
SMSarah K McCann
Sarah K McCann
MMMalcolm R Macleod
Malcolm R Macleod
Background Meta-analysis of preclinical data is used to evaluate the consistency of findings and to inform the design and conduct of future studies. Unlike clinical meta-analysis, preclinical data often involve many heterogeneous studies reporting outcomes from a small number of animals. Here, we review the methodological challenges in preclinical meta-analysis in estimating and explaining heterogeneity in treatment effects. Methods Assuming aggregate-level data, we focus on two topics: (1) estimation of heterogeneity using commonly used methods in preclinical meta-analysis: method of moments (DerSimonian and Laird; DL), maximum likelihood (restricted maximum likelihood; REML) and Bayesian approach; (2) comparison of univariate versus multivariable meta-regression for adjusting estimated treatment effects for heterogeneity. Using data from a systematic review on the efficacy of interleukin-1 receptor antagonist in animals with stroke, we compare these methods, and explore the impact of multiple covariates on the treatment effects. Results We observed that the three methods for estimating heterogeneity yielded similar estimates for the overall effect, but different estimates for between-study variability. The proportion of heterogeneity explained by a covariate is estimated larger using REML and the Bayesian method as compared with DL. Multivariable meta-regression explains more heterogeneity than univariate meta-regression. Conclusions Our findings highlight the importance of careful selection of the estimation method and the use of multivariable meta-regression to explain heterogeneity. There was no difference between REML and the Bayesian method and both methods are recommended over DL. Multiple meta-regression is worthwhile to explain heterogeneity by more than one variable, reducing more variability than any univariate models and increasing the explained proportion of heterogeneity.

4 June 2019 in Environmental Evidence
Verified
Journal Article
Open access
PDF file
NHNeal Haddaway
Neal Haddaway
AFAndrew Feierman
Andrew Feierman
MGMatthew Grainger
Matthew Grainger
CGCharles T. Gray
Charles T. Gray
ETEzgi Tanriver-Ayder
Ezgi Tanriver-Ayder
MWMartin J. Westgate
Martin J. Westgate
Systematic mapping assesses the nature of an evidence base, answering how much evidence exists on a particular topic. Perhaps the most useful outputs of a systematic map are an interactive database of studies and their meta-data, along with visualisations of this database. Despite the rapid increase in systematic mapping as an evidence synthesis method, there is currently a lack of Open Source software for producing interactive visualisations of systematic map databases. In April 2018, as attendees at and coordinators of the first ever Evidence Synthesis Hackathon in Stockholm, we decided to address this issue by developing an R-based tool calledEviAtlas,an Open Access (i.e. free to use) and Open Source (i.e. software code is freely accessible and reproducible) tool for producing interactive, attractive tables and figures that summarise the evidence base. Here, we present our tool which includes the ability to generate vital visualisations for systematic maps and reviews as follows: a complete data table; a spatially explicit geographical information system (Evidence Atlas); Heat Maps that cross-tabulate two or more variables and display the number of studies belonging to multiple categories; and standard descriptive plots showing the nature of the evidence base, for example the number of studies published per year or number of studies per country. We believe thatEviAtlaswill provide a stimulus for the development of other exciting tools to facilitate evidence synthesis.

20 May 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
GCGillian L Currie
Gillian L Currie
HAHelena N Angel-Scott
Helena N Angel-Scott
LCLesley Colvin
Lesley Colvin
FCFala Cramond
Fala Cramond
KHKaitlyn Hair
Kaitlyn Hair
ESEmily S Sena
Emily S Sena
We report a systematic review and meta-analysis of research using animal models of chemotherapy-induced peripheral neuropathy (CIPN). We systematically searched 5 online databases in September 2012 and updated the search in November 2015 using machine learning and text mining to reduce the screening for inclusion workload and improve accuracy. For each comparison, we calculated a standardised mean difference (SMD) effect size, and then combined effects in a random-effects meta-analysis. We assessed the impact of study design factors and reporting of measures to reduce risks of bias. We present power analyses for the most frequently reported behavioural tests; 337 publications were included. Most studies (84%) used male animals only. The most frequently reported outcome measure was evoked limb withdrawal in response to mechanical monofilaments. There was modest reporting of measures to reduce risks of bias. The number of animals required to obtain 80% power with a significance level of 0.05 varied substantially across behavioural tests. In this comprehensive summary of the use of animal models of CIPN, we have identified areas in which the value of preclinical CIPN studies might be increased. Using both sexes of animals in the modelling of CIPN, ensuring that outcome measures align with those most relevant in the clinic, and the animal’s pain contextualised ethology will likely improve external validity. Measures to reduce risk of bias should be employed to increase the internal validity of studies. Different outcome measures have different statistical power, and this can refine our approaches in the modelling of CIPN. Many frequently used and effective cancer chemotherapies can cause a disabling side effect that features pain, numbness, tingling, and sensitivity to cold and heat in the extremities known as chemotherapy-induced peripheral neuropathy (CIPN). There are currently no effective therapies to treat or prevent this condition, and animal models have been developed to address this. It is important that experiments using animal models of CIPN are robust and valid if they are to effectively help patients. We used a systematic approach to identify all 337 studies that have been published describing the use of animal models of CIPN. We were able to identify that many studies are imperfect in their experimental design, use only male animals, and assess outcomes with limited relevance to the human condition. Based on a meta-analysis, we provide guidance to the CIPN animal modelling community to guide future experiments that may improve their utility and validity.

17 October 2019
Verified
Book Chapter
Open access
PDF file
MMMalcolm R. Macleod
Malcolm R. Macleod
ETEzgi Tanriver-Ayder
Ezgi Tanriver-Ayder
KHKaitlyn Hair
Kaitlyn Hair
ESEmily Sena
Emily Sena
Any given research claim can be made with a degree of confidence that a phenomenon is present, with an estimate of the precision of the observed effects and a prediction of the extent to which the findings might hold true under different experimental or real-world conditions. In some situations, the certainty and precision obtained from a single study are sufficient reliably to inform future research decisions. However, in other situations greater certainty is required. This might be the case where a substantial research investment is planned, a pivotal claim is to be made or the launch of a clinical trial programme is being considered. Under these circumstances, some form of summary of findings across studies may be helpful. Summary estimates can describe findings from exploratory (observational) or hypothesis testing experiments, but importantly, the creation of such summaries is, in itself, observational rather than experimental research. The process is therefore particularly at risk from selective identification of literature to be included, and this can be addressed using systematic search strategies and pre-specified criteria for inclusion and exclusion against which possible contributing data will be assessed. This characterises a systematic review (in contrast to nonsystematic or narrative reviews). In meta-analysis, there is an attempt to provide a quantitative summary of such research findings.

24 June 2021 in Journal of EAHIL
Verified
Journal Article
Open access
KHKaitlyn Hair
Kaitlyn Hair
ESEmily S. Sena
Emily S. Sena
EWEmma Wilson
Emma Wilson
GCGillian Currie
Gillian Currie
MMMalcolm Macleod
Malcolm Macleod
BDBroc Drury
Broc Drury
Throughout the global coronavirus pandemic, we have seen an unprecedented volume of COVID-19 researchpublications. This vast body of evidence continues to grow, making it difficult for research users to keep up with the pace of evolving research findings. To enable the synthesis of this evidence for timely use by researchers, policymakers, and other stakeholders, we developed an automated workflow to collect, categorise, and visualise the evidence from primary COVID-19 research studies. We trained a crowd of volunteer reviewers to annotate studies by relevance to COVID-19, study objectives, and methodological approaches. Using these human decisions, we are training machine learning classifiers and applying text-mining tools to continually categorise the findings and evaluate the quality of COVID-19 evidence.

11 May 2019 in OSF Preprints
Verified
Preprint
Open access
NHNeal Haddaway
Neal Haddaway
AFAndrew Feierman
Andrew Feierman
MGMatthew Grainger
Matthew Grainger
CGCharles T. Gray
Charles T. Gray
EAEzgi Tanriver Ayder
Ezgi Tanriver Ayder
MWMartin J. Westgate
Martin J. Westgate
Systematic mapping assesses the nature of an evidence base, answering how much evidence exists on a particular topic. Perhaps the most useful outputs of a systematic map are an interactive database of studies and their meta-data, along with visualisations of this database. Despite the rapid increase in systematic mapping as an evidence synthesis method, there is currently a lack of Open Source software for producing interactive visualisations of systematic map databases. In April 2018, as attendees at and coordinators of the first ever Evidence Synthesis Hackathon in Stockholm, we decided to address this issue by developing an R-based tool called EviAtlas, an Open Access (i.e. free to use) and Open Source (i.e. software code is freely accessible and reproducible) tool for producing interactive, attractive tables and figures that summarise the evidence base. Here, we present our tool which includes the ability to generate vital visualisations for systematic maps and reviews as follows: a complete data table; a spatially explicit geographical information system (Evidence Atlas); Heat Maps that cross-tabulate two or more variables and display the number of studies belonging to multiple categories; and standard descriptive plots showing the nature of the evidence base, for example the number of studies published per year or number of studies per country. We believe that EviAtlas will provide a stimulus for the development of other exciting tools to facilitate evidence synthesis.